Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201712-16 Development of NRP1 targeting antibody(Oncology, Protein) [2019-03-29]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

Development of NRCR Target Therapeutic Anticancer Drug (IRCR-101)

Unmet Medical Need & Target Patients

Analysis of IRCR-101 response patients using Tissue microarray (TMA) of 1488 patients with intractable solid tumors: liver cancer (38.6%), prostate cancer (36.9%), colon cancer (32.4%), breast cancer (20%), kidney cancer (19.5%), brain cancer (17.5%) and lung cancer (15.3%)

NRP1 antibody trial was performed by Genentech, but failed in clinical trial phase 1 due to nonspecific clearance, proteinuria, and thrombocytopenia. Antibody was screened using PDCP (patient derived cell panning) technique. PDCP method selected only those antibodies that specifically bind to and internalize cancer cells. Antibodies selected using the PDCP technique can maximize anticancer efficacy by minimizing the side effects of competing antibodies.

Status

Target translation research: Clinical data confirmed that the survival rate of patients with NRP1 overexpression was decreased (p = 1.3E-05)

Chemical property: KD=42.2 nM (SPR assay)

Tumor-specificity: specifically binding and internalization to cancer cell

Efficacy test: In vitro (40-60% inhibition of cancer cell migration), In vivo (30-40% inhibition of tumor growth)

Short-term PK: clearance within 24 hours after injection

Pre-toxicity test: No abnormality in liver and kidney function (180 mg/kg)

Clinical application: 26.1% of 7 solid tumors species (n=1488)

CMC/Production: 99% pure IgG antibody production (100 mg/L) in the Expi293TM system.

Intellectual Property

The patent of IRCR-101 (ANTIBODY BINDING TO NEUROPILIN 1 AND USE THEREOF) was granted in Korea, and filed in several key territories.

Competitive Advantages

Minimal side effect of NRP1 target treatment expressed in normal cells and maximization of anticancer efficacy for posttranslational modified NRP1 high expression patient group Strategy for L/O with antibody development platform using PDCD technique and antibody

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code